The promise of glaucoma genetic studies is simple: defining genetic risk factors predisposing people toward glaucoma empowers the design of new therapeutic strategies. All current glaucoma medications and surgeries target the same risk factor: intraocular pressure. This strategy is often adequate, but for some patients alternative approaches could be of substantial benefit. By promoting new opportunities for early detection and additional options for medical intervention, the potential long-term benefits of studying glaucoma genetics are clear. The actual work to discover the genetic causes of glaucoma is far from simple. Given the biological intricacies of the anatomy and physiology involved in glaucoma, most geneticists have long suspected that the glaucoma phenotype would involve equally intricate genetic pathways.
glaucomas associated with pigment dispersion or exfoliation syndrome). An interesting example of glaucoma genetics that benefited from this strategy comes from studies of the myocilin gene and its role in glaucoma.
The discovery of myocilin as a glaucoma-causing gene was a culmination of multiple experimental approaches. In one line of work, the myocilin protein was identified by cellular studies of the trabecular meshwork. 5 Independently, a positional cloning approach with an unusually large family pedigree affected by autosomal dominant juvenile open-angle glaucoma led to the identification of disease-causing mutations within the myocilin gene on chromosome 1q. 6, 7 Having initially identified myocilin's contribution to this early-onset form of glaucoma, subsequent studies then went on to test whether myocilin mutations are also associated with the much more common and later onset primary open-angle form of glaucoma. 7 A series of population-based screens has indeed indicated that approximately 3-5% of primary open-angle glaucoma cases worldwide are attributable to defects in the myocilin gene. 8, 9 More recently, several groups have generated myocilin mouse models. [10] [11] [12] [13] Combined, these efforts are collectively contributing to a better understanding of myocilin function and bringing potential therapies derived from this knowledge ever closer. 
A Pessimistic

Success in Exfoliation Syndrome-Identification of Lysyl Oxidase-like Protein 1 Gene
Significant advances in glaucoma genetics have been precipitated by studies unraveling the genetic factors of exfoliation syndrome.
Exfoliation syndrome has long been appreciated to have strong hereditary contributions, 15, 16 but until recently no causative mutations had been identified. In a large genome-wide association study among Scandinavian glaucoma patients (14,672 controls and 274 patients with exfoliation syndrome), the lysyl oxidase-like protein 1 (LOXL1) gene (Loxl1) has been identified as the first known genetic risk factor contributing to exfoliation syndrome. 17 A strong association was detected between exfoliation syndrome and two single nucleotide polymorphism (SNP) genetic markers in LOXL1. The high-risk alleles defined by these markers occur within the vast majority of patients with exfoliation syndrome. Remarkably, individuals homozygous for both markers have about a 700-fold increased risk for exfoliation syndrome.
If the risk associated with these alleles could be avoided, it would be predicted to eliminate over 99% of exfoliation syndrome cases. 17 In addition to the importance to exfoliation syndrome, these findings also have an important broader implication. As with LOXL1 in exfoliation syndrome, there could also be additional glaucoma-associated genes in other forms of glaucoma with very large influences that remain to be identified. Perhaps with recent technological advancements, such as the ability to readily perform high-density genome-wide genetic association studies, the years to come will bring many more similar advances.
Toward a Genetic Test for Exfoliation Syndrome
Since the initial discovery of the role of LOXL1, there has been a flurry of 
Conclusion
The genetic pathways involved in susceptibility to many common diseases are intricate and often difficult to dissect. Glaucoma is no exception. The recent discovery of the LOXL1 gene as a genetic risk factor for exfoliation syndrome has suggested that some glaucoma genes with very large influence remain to be identified. Given the power of recent technologic advances, the overall future appears bright for glaucoma genetics. However, the example of LOXL1 also emphasizes what most geneticists have long suspected: glaucoma is a multifactorial disease. Thus, in moving forward, it will be important to use experimental approaches that reduce complexity, including the synergistic use of genetic approaches in mice to identify additional genes of importance. n Toward a Genetic Understanding of Glaucoma-Breakthroughs and Challenges
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